Skip to main content

NSAIDs and Analgesics

NSAIDs and analgesics play several roles in urology: (1) acute renal colic — the most evidence-based application, where NSAIDs are first-line over opioids; (2) perioperative pain management in urologic surgery; (3) ureteral stent symptoms; (4) analgesia during observation / medical expulsive therapy (MET) for ureteral stones; (5) chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS); (6) interstitial cystitis / bladder pain syndrome (IC/BPS); (7) bladder cancer chemoprevention (investigational); and (8) urinary tract analgesia (phenazopyridine). NSAIDs carry significant nephrotoxicity risk that is amplified in urologic patients (obstructive uropathy, solitary kidney, CKD, RAAS-inhibitor use), and the opioid-stewardship movement has fundamentally reshaped analgesic prescribing in the field.[1][2][3][4]

For the analgesia comparator classes — broadly framed as nonnarcotic methods of pain management[9] — see Gabapentinoids, SNRIs, and Tricyclic antidepressants.

Mechanism — Why NSAIDs Work in the LUT​

NSAIDs inhibit COX → reduced prostaglandin synthesis. The class effects are urologic at four levels:[2]

  1. Renal pelvis and ureter — prostaglandins drive ureteral spasm, mucosal inflammation, and renal vasodilation around an obstructing stone. NSAIDs blunt all three, lowering urine output and intra-pelvic pressure — a fundamentally different mechanism from opioids, which only mask central pain
  2. Ureteral smooth muscle — reduced peristaltic spasm; a proposed, not established, stone-expulsion effect[5]
  3. Bladder and prostate — COX-2 is upregulated in inflamed prostate and urothelium; these mechanisms do not establish disease modification in CP/CPPS or IC/BPS[6]
  4. Bladder cancer biology — COX-2 is overexpressed in transitional cell carcinoma; COX-2 inhibition induces apoptosis, blocks EMT, and reduces tumor growth in preclinical models[7][8]

Urologic Applications at a Glance​

ApplicationPreferred agent(s)EvidencePosition
Acute renal colicDiclofenac IM, ibuprofen IV, ketorolac IVCochrane + multiple meta-analyses[1][2][10]EAU first choice after individual risk assessment; CDC favors nonopioid therapy[19]
Post-ureteroscopy painKetorolac PO/IVSKOPE RCT[11]Expert consensus: 0 opioid tablets acceptable[4]
Ureteral stent symptomsNSAIDs as adjunctSystematic reviews[15]Recommended with α-blockers ± antimuscarinics
Pain during stone observation / METNSAID if appropriateAnalgesia is established; celecoxib expulsion data are limited[12]Do not prescribe celecoxib specifically to promote expulsion[49]
CP/CPPSIbuprofen, diclofenac, celecoxib (short-term)Cochrane and network meta[6][23][24]Small average benefit; low-certainty evidence
IC/BPSNSAIDs (general principles)AUA Clinical Principle[3][25]Pain-management framework only
Bladder cancer chemopreventionCelecoxibNegative randomized trials[13][14]Not recommended (CV risk; negative)
Perioperative urologic surgeryKetorolac, ibuprofen, celecoxib + acetaminophenMeta-analyses; ERAS[21][22]Core of multimodal opioid-sparing pathways

Acute Renal Colic — the primary urologic application​

The most evidence-based use of NSAIDs in urology, supported by multiple Cochrane reviews and large meta-analyses.

Headline evidence​

  • Cochrane 2025 (29 RCTs, n = 3,593; search through August 2023): the placebo comparison favored NSAIDs at 30 minutes (MD −3.84 cm on a 10-cm VAS; 95% CI −6.41 to −1.27), but this came from only three studies / 250 participants, with high heterogeneity and low certainty. Agent comparisons, including a possible IV ibuprofen advantage over ketorolac, do not establish a universally best NSAID. Evidence about harms was uncertain; IV and IM routes probably have similar analgesic effects.[2]
  • Pathan 2018 meta (36 RCTs, n = 4,887): NSAIDs marginally outperform opioids at 30 min (small mean difference with substantial heterogeneity); fewer rescue treatments (NNT 11) and lower vomiting (NNT 5) vs opioids; fewer rescue treatments than paracetamol (RR 0.56; p < 0.05)[1]
  • Network comparisons: indirect rankings of drug / route combinations should not override renal, gastrointestinal and cardiovascular risk, contraindications, or local availability.[10] EAU 2026 recommends an NSAID as first choice when appropriate, and decompression or stone removal for analgesia-refractory colic.[49]
  • Pathan 2016 Lancet RCT (1,645 randomized; 1,644 intention-to-treat): at least 50% pain reduction by 30 minutes occurred in 68% with IM diclofenac, 66% with IV paracetamol and 61% with IV morphine. Diclofenac was superior to morphine in the primary analysis (p = 0.0187); paracetamol was not (p = 0.0629). Both comparisons favored the nonopioid drug in the smaller imaging-confirmed, per-protocol population; that does not replace the primary analysis.[18]
  • CDC Guideline 2022: opioids are not recommended as first-line therapy for kidney-stone pain[19]

Agent selection and dosing boundaries​

The following are adult examples, not interchangeable prescriptions. Select the agent, route and dose for the patient and the local product label.

AgentExample / boundaryKey limitation
Diclofenac75 mg IM was used in the large renal-colic trialCheck cardiovascular, GI and renal risk; formulation availability differs by country[18][49]
KetorolacUS single IV dose: 30 mg if under 65; 15 mg if ≥65, renally impaired or under 50 kgUse lower effective doses when appropriate. All IV/IM and oral treatment combined must stay within 5 days; US oral dosing is continuation of parenteral therapy, not initial therapy[47]
IbuprofenOral or IV according to clinical need and the product labelComparative studies do not justify routinely choosing the highest IV dose[2]
Acetaminophen / paracetamol IV≥50 kg: 1,000 mg every 6 h or 650 mg every 4 h; under 50 kg requires weight-based dosingInfuse over 15 minutes; include every route and combination product in the total dose (see below)[48]
NSAID safety before prescribing

Ketorolac is contraindicated with active or prior peptic ulcer / GI bleeding, advanced renal impairment or risk of renal failure from volume depletion, concurrent aspirin / other NSAIDs, and CABG surgery; it is also contraindicated as prophylactic analgesia before major surgery. NSAIDs carry serious GI bleeding and cardiovascular thrombotic risks. Check bleeding risk and anticoagulants as well as renal function. Do not assume a COX-2-selective drug removes these risks.[47]

FDA recommends limiting NSAIDs at 20–30 weeks of pregnancy because of fetal renal dysfunction / oligohydramnios, and avoiding them from about 30 weeks because of premature ductus arteriosus closure. If use at 20–30 weeks is necessary, use the lowest dose for the shortest duration; consider amniotic-fluid monitoring if treatment exceeds 48 hours.[50]

Perioperative Pain Management​

NSAIDs are the foundation of opioid-sparing multimodal analgesia in urologic surgery.

Opioid-sparing magnitude (systematic review of 32 studies)[21]​

  • Diclofenac reduces opioid consumption 17–50%
  • Ketorolac 9–66%
  • Ibuprofen 22–46%
  • Ketoprofen 34–66%

The review reported reductions in opioid-related adverse effects. Absence of a bleeding signal in these trials does not establish safety for every operation, patient, NSAID or dose; assess the specific procedure and contraindications.

SKOPE RCT — ketorolac vs oxycodone post-URS[11]​

This double-blind noninferiority trial included 81 patients and compared as-needed ketorolac 10 mg with oxycodone 5 mg over postoperative days 1–5. Both groups also received three oxycodone rescue tablets. Pain outcomes supported ketorolac as an alternative for suitable patients, with fewer days confined to bed (1.3 vs 2.3; p = 0.02). It supports reducing routine opioid prescribing, not withholding rescue analgesia or ignoring ketorolac contraindications / the US oral-continuation restriction.[47]

Opioid-stewardship results in urology​

NOPIOIDS protocol (Mian 2023)[17]​

This single-center, nonrandomized cohort study followed 647 opioid-naive patients through sequential prescribing pathways after radical cystectomy, radical / partial nephrectomy, or radical prostatectomy:

  • Discharge opioid prescription rate: 80.9% (control) → 57.9% (lead-in) → 2.2% (NOPIOIDS)
  • Median tablets prescribed: 14 → 4 → 0 (p < 0.001)
  • The pathway recorded low pain scores and high satisfaction, with no detected increase in complications. Selection, temporal confounding and incomplete patient-reported follow-up limit causal or universal safety claims; individualized rescue access remains necessary.

ORIOLES — post-prostatectomy[22][46]​

In 205 RP patients with 100% follow-up, median prescribed 225 mg OMEQ but median used 22.5 mg OMEQ — 77% of prescribed opioids unused; 84% required ≤ 112.5 mg OMEQ; only 9% appropriately disposed of leftover medication. Prescribing more was independently associated with greater use.

Expert-panel prescribing ranges[4]​

Koo and colleagues’ multidisciplinary Delphi consensus concerned opioid-naive patients without chronic pain undergoing 16 endourological / minimally invasive procedures. It is an expert consensus, not a universal AUA drug limit. The minimum suggested quantity was zero; procedure-specific upper ranges varied from zero to 15 oxycodone 5-mg-equivalent tablets. Match prescribing to expected need, contraindications to nonopioid drugs, prior opioid exposure and access to reassessment.[4][16]

Ureteral Stent–Related Symptoms​

NSAIDs are part of multimodal stent-symptom pharmacotherapy.[15]

  • Alpha-blockers carry the strongest monotherapy evidence
  • NSAIDs target the inflammatory and pain components
  • Antimuscarinics target the urinary symptom components
  • Add treatments selectively rather than stacking drugs according to indirect rankings. Sedation and respiratory risks matter if considering Gabapentinoids; the cited 2016 stent review does not establish a preferred pregabalin combination.[15]

Medical Expulsive Therapy​

NSAIDs treat pain during conservative stone management; they are not established stone-expulsive treatment. EAU 2026 recommends offering off-label α-blockers as an option for distal ureteral stones 5–10 mm in patients suitable for observation.[49]

  • Lv & Tang 2014 (RCT, n = 105): naftopidil + celecoxib 200 mg achieved the highest distal-stone expulsion (94.3%) vs naftopidil alone (82.9%) or celecoxib alone (60.6%) (p < 0.05)[12]
  • Small adjunct trials and mechanistic reviews are insufficient to recommend adding celecoxib specifically for stone passage.[5]

CP/CPPS​

AUA 2025 allows anti-inflammatory agents as one component of multimodal CP/CPPS pain management, and discourages long-term use because of harms. Average improvements in reviews are small and uncertain; individual response should be reassessed.[6][23][24][51]

  • Cochrane 2019 (7 RCTs, n = 372 men): anti-inflammatories vs placebo — NIH-CPSI MD −2.5 (95% CI −3.74 to −1.26), a small average difference with low-certainty evidence; a within-person 6-point response threshold is not identical to a between-group mean difference[23]
  • Network meta-analysis 2022 (5 RCTs, n = 191): NIH-CPSI MD −1.7 (p = 0.03) — again below MCID[24]
  • Use an individualized short trial within multimodal treatment; the guideline does not prescribe a universal 4–6-week high-dose ibuprofen course. Routine opioid treatment is inappropriate for this chronic condition.[6][51]
  • Reasonable as part of multimodal therapy; limit to short courses to minimize nephrotoxicity and GI risk.

IC/BPS​

The 2022 AUA IC/BPS Guideline addresses pain pharmacology as a Clinical Principle: pain management for IC/BPS should mirror other chronic-pain conditions; non-opioid agents should be used preferentially; pain management alone is not sufficient — multimodal therapy is essential.[3][25]

Evidence does not establish NSAIDs as disease-specific IC/BPS treatment. Use for selected symptoms within the broader bladder-directed and pain-management plan; reassess benefit and toxicity.

Phenazopyridine — the urinary-tract analgesic​

Phenazopyridine offers short-term symptom relief and does not treat infection or its cause. The cited US prescription product is marketed as unapproved drug other; a DailyMed listing does not establish FDA approval. Follow the phenazopyridine hub for dosing, the two-day limit with antibacterials, renal contraindication, discoloration and methemoglobinemia / G6PD precautions.[26] TRPM8 inhibition is a proposed mechanism from laboratory work, not proof of clinical benefit for chronic bladder pain.[27]

Celecoxib and Bladder Cancer Chemoprevention​

Strong preclinical rationale; clinical trials are negative, and CV risk precludes routine use.

Preclinical (strong)[7][8][29][30][31]​

  • Celecoxib reduced bladder-cancer incidence 65–95% in rat models when given preventively
  • Mechanisms include COX-2-dependent and -independent pathways: apoptosis, anti-EMT (miR-145 / TGFBR2 / Smad3), anti-inflammatory, anti-proliferative, antioxidant
  • Preventive but not curative efficacy — curative dosing may aggravate tumor malignancy

Clinical (negative)​

TrialDesignResult
BOXIT (Kelly 2019)Phase III RCT, n = 472, intermediate / high-risk NMIBCNo significant benefit: 3-year recurrence-free rates 68% vs 64% (HR 0.82, 95% CI 0.60–1.12; p = 0.2). Exploratory pT1 subgroup findings do not establish an indication. Serious CV events were numerically higher (5.2% vs 1.7%; p = 0.07)[13]
Sabichi 2011RCT, n = 146, high-risk NMIBCDid not significantly prolong time to recurrence (p = 0.17; median follow-up 2.49 years). 12-month recurrence-free rates were 88% vs 78%; adjusted HR 0.69 (95% CI 0.37–1.29). Exploratory recurrent-event analysis did not establish benefit[14]

Celecoxib is not recommended for bladder-cancer chemoprevention.

NSAIDs and Erectile / Gonadal Function​

The relationship between NSAIDs and ED is controversial and likely confounded by indication.

StudyDirection
Gleason 2011 (n = 80,966)Regular NSAID use associated with ED (aOR 1.38)[32]
Shiri 2006 (n = 1,126)NSAID use raised ED risk (IDR 2.0)[33]
Senbel preclinicalIndomethacin reduced rat erectile responses; diclofenac less; celecoxib unaffected[34]
Patel PCPT (n = 4,726)After controlling for indication, NSAID use not associated with ED — apparent association attributable to confounding[35]
Halpern NHANES (n = 3,749)Regular NSAID use not associated with testosterone, AMH, or compensated hypogonadism[36]
Li 2018 systematic reviewMixed; methodologically heterogeneous[37]

Practical message: current evidence does not support counseling patients that NSAIDs cause ED, although non-selective COX inhibitors (especially indomethacin) may have direct effects on erectile physiology in preclinical models.

Nephrotoxicity — the critical urologic concern​

NSAID nephrotoxicity is amplified in urologic patients.[38][39][40][41]

Mechanisms​

  1. Hemodynamic AKI (most common, usually reversible) — NSAIDs blunt prostaglandin-mediated compensatory vasodilation in low-perfusion states → reduced GFR
  2. Acute interstitial nephritis (rare, idiosyncratic) — any NSAID
  3. Renal papillary necrosis — chronic use
  4. Electrolyte disturbance — sodium / water retention, hyperkalemia, hyponatremia
  5. CKD — regular use may raise CKD incidence; relationship with progression less clear

Risk factors that matter for the urologist​

  • Pre-existing CKD (CrCl < 60)
  • Volume depletion / dehydration
  • Concurrent RAAS inhibitors and diuretics (the "triple whammy")
  • Advanced age (> 65)
  • Solitary kidney — common after nephrectomy
  • Bilateral or high-grade obstruction
  • Heart failure, cirrhosis

Practical implications​

  • Renal colic — NSAIDs remain first-line in patients with adequate renal function; check baseline function and avoid in significant CKD, dehydration, or bilateral obstruction[1][41]
  • Solitary-kidney patients — favor acetaminophen as primary analgesic
  • Stone formers on thiazides — combination raises nephrotoxicity risk
  • Lowest effective dose for the shortest possible time is the universal rule[39][40]

Acetaminophen / Paracetamol in Urology​

A first-line analgesic when NSAIDs are contraindicated.

  • Renal colic — IV paracetamol is an alternative when NSAIDs are unsuitable; the Pathan intention-to-treat analysis did not establish superiority over morphine[1][18][20]
  • Perioperative — core component of multimodal analgesia in ERAS protocols; reduces opioid consumption when paired with NSAIDs; the cited emergency-general-surgery guideline supports its use but does not establish a universal order of administration for urologic procedures[42]
  • Renal safety — often preferable to NSAIDs when renal risk is high, but dose must reflect body weight, liver health and total exposure; little evidence that chronic paracetamol monotherapy causes CKD or analgesic nephropathy; a suitable first-line choice in CKD with dose individualization in advanced renal failure[43][44][45]
  • CP/CPPS — recommended alongside short-term NSAIDs; opioids should be avoided[6]

Acetaminophen dose safeguards​

The cited IV label limits total exposure from all routes and all combination products to 4 g/24 h for adults ≥50 kg. Under 50 kg, use 15 mg/kg every 6 h or 12.5 mg/kg every 4 h, maximum 75 mg/kg/day. These are ceilings, not goals; lower limits may be needed with hepatic risk, malnutrition or alcohol use. Severe hepatic impairment / severe active liver disease is a contraindication. Avoid accidental duplication with opioid–acetaminophen products.[48]

New nonopioid option — suzetrigine​

Suzetrigine (Journavx), a peripheral NaV1.8 inhibitor, received FDA approval in January 2025 for moderate-to-severe acute pain in adults. Two phase-3 trials after abdominoplasty (n = 1,118) and bunionectomy (n = 1,073) showed benefit over placebo over 48 hours, but neither established superiority to hydrocodone / acetaminophen. These were not urologic or chronic pelvic-pain trials.[52][53]

The July 2026 label includes postoperative pain and notes that acute-pain use beyond 14 days has not been studied. Strong CYP3A inhibitors are contraindicated; moderate inhibitors require dose reduction, strong / moderate inducers should be avoided, and severe hepatic impairment is a reason to avoid treatment. Check its effects on CYP3A substrates and hormonal contraception. This is an additional acute-pain option, not an established replacement for GU-specific multimodal pathways.[28]

Opioid Stewardship in Urology — Key Principles​

  • Opioids are not first-line for kidney-stone pain[19]
  • When opioids are warranted, prescribe immediate-release at the lowest effective dose for the shortest expected duration[19]
  • Maximize NSAIDs and acetaminophen; explore non-pharmacologic options
  • Expert consensus offers procedure-specific ranges, for opioid-naive patients without chronic pain; do not apply those ranges automatically to other populations[4]
  • NOPIOIDS-style protocols support reducing routine discharge opioid prescribing after major cancer surgery, with patient education and reassessment; the evidence is observational[17]
  • 77% of opioids prescribed after RP are unused — calibrate prescribing accordingly using initiatives like ORIOLES[22][46]

Clinical Positioning​

  • Renal colic → NSAID first-line in patients with adequate renal function (IM diclofenac, IV ibuprofen, IV ketorolac); IV paracetamol is the alternative when NSAIDs are contraindicated; opioids may be needed when nonopioid treatment is contraindicated or inadequate[1][2][10][19]
  • Post-URS, post-cystectomy, post-RP — multimodal NSAID + acetaminophen is the standard; SKOPE and NOPIOIDS show 0–minimal opioid prescribing is feasible[11][17]
  • Stent symptoms — NSAIDs as adjunct to α-blockers ± antimuscarinics; select adjuncts by symptoms and adverse-effect risk[15]
  • MET — α-blockers are an option for selected distal stones; NSAIDs provide analgesia and are not established expulsive agents[12]
  • CP/CPPS — an individualized short NSAID trial may fit multimodal care; average benefit is small and evidence uncertain[6]
  • IC/BPS — NSAIDs as part of general non-opioid pain management; multimodal therapy required[3]
  • Phenazopyridine provides short-term urinary symptom relief; 2-day limit with antibacterials, contraindicated in renal insufficiency[26]
  • Bladder cancer chemoprevention — celecoxib is not recommended despite preclinical signal[13][14]
  • Nephrotoxicity is the dominant safety concern in urologic patients — assess renal function, assess volume depletion, interacting drugs, CKD and obstruction rather than assuming safety from a normal single creatinine, use the lowest effective dose for the shortest possible time[38][39][40][41]
  • Don't counsel patients that NSAIDs cause ED — the apparent association is confounded by indication[35][37]

See Also​

References​

1. Pathan SA, Mitra B, Cameron PA. "A systematic review and meta-analysis comparing the efficacy of nonsteroidal anti-inflammatory drugs, opioids, and paracetamol in the treatment of acute renal colic." Eur Urol. 2018;73(4):583–595. doi:10.1016/j.eururo.2017.11.001

2. Afshar K, Gill J, Mostafa H, Noparast M. "Nonsteroidal anti-inflammatory drugs (NSAIDs) for acute renal colic." Cochrane Database Syst Rev. 2025;3:CD006027. doi:10.1002/14651858.CD006027.pub3

3. Clemens JQ, Erickson DR, Varela NP, Lai HH. "Diagnosis and treatment of interstitial cystitis/bladder pain syndrome." J Urol. 2022;208(1):34–42. doi:10.1097/JU.0000000000002756

4. Koo K, Faisal F, Gupta N, et al. "Recommendations for opioid prescribing after endourological and minimally invasive urological surgery: an expert panel consensus." J Urol. 2020;203(1):151–158. doi:10.1097/JU.0000000000000514

5. Lim I, Sellers DJ, Chess-Williams R. "Current and emerging pharmacological targets for medical expulsive therapy." Basic Clin Pharmacol Toxicol. 2022;130(Suppl 1):16–22. doi:10.1111/bcpt.13613

6. Borgert BJ, Wallen EM, Pham MN. "Prostatitis." JAMA. 2025;334(11):1003–1013. doi:10.1001/jama.2025.11499

7. Grubbs CJ, Lubet RA, Koki AT, et al. "Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats." Cancer Res. 2000;60(20):5599–5602.

8. Liu X, Wu Y, Zhou Z, et al. "Celecoxib inhibits the epithelial-to-mesenchymal transition in bladder cancer via the miRNA-145/TGFBR2/Smad3 axis." Int J Mol Med. 2019;44(2):683–693. doi:10.3892/ijmm.2019.4241

9. Finnerup NB. "Nonnarcotic methods of pain management." N Engl J Med. 2019;380(25):2440–2448. doi:10.1056/NEJMra1807061

10. Gu HY, Luo J, Wu JY, et al. "Increasing nonsteroidal anti-inflammatory drugs and reducing opioids or paracetamol in the management of acute renal colic: based on three-stage study design of network meta-analysis of randomized controlled trials." Front Pharmacol. 2019;10:96. doi:10.3389/fphar.2019.00096

11. Fedrigon D, Faris A, Kachroo N, et al. "SKOPE — Study of Ketorolac vs Opioid for Pain after Endoscopy: a double-blinded randomized control trial in patients undergoing ureteroscopy." J Urol. 2021;206(2):373–381. doi:10.1097/JU.0000000000001772

12. Lv JL, Tang QL. "Comparative evaluation of efficacy of use of naftopidil and/or celecoxib for medical treatment of distal ureteral stones." Urolithiasis. 2014;42(6):541–547. doi:10.1007/s00240-014-0708-6

13. Kelly JD, Tan WS, Porta N, et al. "BOXIT — a randomised phase III placebo-controlled trial evaluating the addition of celecoxib to standard treatment of transitional cell carcinoma of the bladder (CRUK/07/004)." Eur Urol. 2019;75(4):593–601. doi:10.1016/j.eururo.2018.09.020

14. Sabichi AL, Lee JJ, Grossman HB, et al. "A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer." Cancer Prev Res (Phila). 2011;4(10):1580–1589. doi:10.1158/1940-6207.CAPR-11-0036

15. Koprowski C, Kim C, Modi PK, Elsamra SE. "Ureteral stent-associated pain: a review." J Endourol. 2016;30(7):744–753. doi:10.1089/end.2016.0129

16. Cabo JJS, Miller NL. "Nonopioid pain management pathways for stone disease." J Endourol. 2024;38(2):108–120. doi:10.1089/end.2023.0266

17. Mian BM, Singh Z, Carnes K, et al. "Implementation and assessment of no opioid prescription strategy at discharge after major urologic cancer surgery." JAMA Surg. 2023;158(4):378–385. doi:10.1001/jamasurg.2022.7652

18. Pathan SA, Mitra B, Straney LD, et al. "Delivering safe and effective analgesia for management of renal colic in the emergency department: a double-blind, multigroup, randomised controlled trial." Lancet. 2016;387(10032):1999–2007. doi:10.1016/S0140-6736(16)00652-8

19. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. "CDC clinical practice guideline for prescribing opioids for pain — United States, 2022." MMWR Recomm Rep. 2022;71(3):1–95. doi:10.15585/mmwr.rr7103a1

20. Al-Terki A, Hussain J, El-Nahas AR, et al. "Parecoxib vs paracetamol for treatment of acute renal colic due to ureteric calculi: a randomized controlled trial." Urology. 2021;149:76–80. doi:10.1016/j.urology.2020.12.017

21. Martinez L, Ekman E, Nakhla N. "Perioperative opioid-sparing strategies: utility of conventional NSAIDs in adults." Clin Ther. 2019;41(12):2612–2628. doi:10.1016/j.clinthera.2019.10.002

22. Patel HD, Srivastava A, Patel ND, et al. "A prospective cohort study of postdischarge opioid practices after radical prostatectomy: the ORIOLES initiative." Eur Urol. 2019;75(2):215–218. doi:10.1016/j.eururo.2018.10.013

23. Franco JV, Turk T, Jung JH, et al. "Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome." Cochrane Database Syst Rev. 2019;10:CD012552. doi:10.1002/14651858.CD012552.pub2

24. Qin Z, Zhang C, Guo J, et al. "Oral pharmacological treatments for chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis of randomised controlled trials." EClinicalMedicine. 2022;48:101457. doi:10.1016/j.eclinm.2022.101457

25. Imamura M, Scott NW, Wallace SA, et al. "Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis." Cochrane Database Syst Rev. 2020;7:CD013325. doi:10.1002/14651858.CD013325.pub2

26. Phenazopyridine hydrochloride tablets: product labeling. DailyMed, July 27, 2026; unapproved drug other. Label.

27. Luyts N, Daniluk J, Freitas ACN, et al. "Inhibition of TRPM8 by the urinary tract analgesic drug phenazopyridine." Eur J Pharmacol. 2023;942:175512. doi:10.1016/j.ejphar.2023.175512

28. JOURNAVX (suzetrigine): US prescribing information, revised July 2026. Primary source. Accessed September 12, 2026.

29. Parada B, Sereno J, Reis F, et al. "Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyclooxygenase-2 inhibition as chemoprevention for rat bladder carcinogenesis." Cancer Biol Ther. 2009;8(17):1615–1622. doi:10.4161/cbt.8.17.9199

30. Dhawan D, Jeffreys AB, Zheng R, Stewart JC, Knapp DW. "Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells." Mol Cancer Ther. 2008;7(4):897–904. doi:10.1158/1535-7163.MCT-07-0313

31. Sereno J, Parada B, Reis F, et al. "Preventive but not curative efficacy of celecoxib on bladder carcinogenesis in a rat model." Mediators Inflamm. 2010;2010:380937. doi:10.1155/2010/380937

32. Gleason JM, Slezak JM, Jung H, et al. "Regular nonsteroidal anti-inflammatory drug use and erectile dysfunction." J Urol. 2011;185(4):1388–1393. doi:10.1016/j.juro.2010.11.092

33. Shiri R, Koskimäki J, Häkkinen J, et al. "Effect of nonsteroidal anti-inflammatory drug use on the incidence of erectile dysfunction." J Urol. 2006;175(5):1812–1815. doi:10.1016/S0022-5347(05)01000-1

34. Senbel AM. "Functional inhibition of erectile process in rats by indomethacin." World J Urol. 2011;29(4):523–527. doi:10.1007/s00345-010-0600-0

35. Patel DP, Schenk JM, Darke A, et al. "Non-steroidal anti-inflammatory drug (NSAID) use is not associated with erectile dysfunction risk: results from the Prostate Cancer Prevention Trial." BJU Int. 2016;117(3):500–506. doi:10.1111/bju.13264

36. Halpern JA, Fantus RJ, Chang C, et al. "Effects of nonsteroidal anti-inflammatory drug (NSAID) use upon male gonadal function: a national, population-based study." Andrologia. 2020;52(4):e13542. doi:10.1111/and.13542

37. Li T, Wu C, Fu F, et al. "Association between use of aspirin or non-aspirin non-steroidal anti-inflammatory drugs and erectile dysfunction: a systematic review." Medicine (Baltimore). 2018;97(28):e11367. doi:10.1097/MD.0000000000011367

38. Ković SV, Vujović KS, Srebro D, Medić B, Ilic-Mostic T. "Prevention of renal complications induced by non-steroidal anti-inflammatory drugs." Curr Med Chem. 2016;23(19):1953–1964. doi:10.2174/0929867323666160210125920

39. Whelton A. "Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications." Am J Med. 1999;106(5B):13S–24S. doi:10.1016/s0002-9343(99)00113-8

40. LaForge JM, Urso K, Day JM, et al. "Non-steroidal anti-inflammatory drugs: clinical implications, renal impairment risks, and AKI." Adv Ther. 2023;40(5):2082–2096. doi:10.1007/s12325-023-02481-6

41. Baker M, Perazella MA. "NSAIDs in CKD: are they safe?" Am J Kidney Dis. 2020;76(4):546–557. doi:10.1053/j.ajkd.2020.03.023

42. Coccolini F, Corradi F, Sartelli M, et al. "Postoperative pain management in non-traumatic emergency general surgery: WSES-GAIS-SIAARTI-AAST guidelines." World J Emerg Surg. 2022;17(1):50. doi:10.1186/s13017-022-00455-7

43. Alchin J, Dhar A, Siddiqui K, Christo PJ. "Why paracetamol (acetaminophen) is a suitable first choice for treating mild to moderate acute pain in adults with liver, kidney or cardiovascular disease, gastrointestinal disorders, asthma, or who are older." Curr Med Res Opin. 2022;38(5):811–825. doi:10.1080/03007995.2022.2049551

44. Abbasi M, Teakell J. "Literature review: are NSAIDs harmful and is acetaminophen well tolerated?" Curr Opin Nephrol Hypertens. 2023;32(3):284–289. doi:10.1097/MNH.0000000000000886

45. Blantz RC. "Acetaminophen: acute and chronic effects on renal function." Am J Kidney Dis. 1996;28(1 Suppl 1):S3–S6. doi:10.1016/s0272-6386(96)90561-2

46. Su ZT, Becker REN, Huang MM, et al. "Patient and in-hospital predictors of post-discharge opioid utilization: individualizing prescribing after radical prostatectomy based on the ORIOLES initiative." Urol Oncol. 2022;40(3):104.e9–104.e15. doi:10.1016/j.urolonc.2021.10.007

47. Ketorolac tromethamine injection: US prescribing information. DailyMed. Primary source. Accessed September 12, 2026.

48. Acetaminophen injection: US prescribing information. DailyMed. Primary source. Accessed September 12, 2026.

49. EAU Guidelines on Urolithiasis 2026. Sections 3.4.1–3.4.3. Primary source. Accessed September 12, 2026.

50. FDA. Avoiding NSAIDs in pregnancy at 20 weeks or later because of fetal renal dysfunction and low amniotic fluid. Primary source. Accessed September 12, 2026.

51. AUA. Male Chronic Pelvic Pain Guideline 2025. Anti-inflammatory therapy. Primary source. Accessed September 12, 2026.

52. FDA. Approval of suzetrigine for moderate-to-severe acute pain in adults. January 30, 2025. Primary source. Accessed September 12, 2026.

53. Suzetrigine, a Nonopioid NaV1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials. 2025. Primary source. Accessed September 12, 2026.